In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 251 to 300 of 424

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Obesity: prevention and lifestyle management (QS update)	Quality standard	TBC
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]	Technology appraisal guidance	TBC
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]	Technology appraisal guidance	TBC
Olaparib for maintenance treatment of BRCA-negative platinum-sensitive relapsed ovarian, fallopian tube or primary peritoneal cancer [ID6205]	Technology appraisal guidance	TBC
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]	Technology appraisal guidance	TBC
Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]	Technology appraisal guidance	TBC
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]	Highly specialised technology	TBC
Omaveloxolone for treating Friedreich's ataxia in people 16 years and over ID6423	Technology appraisal guidance	13 August 2025
Omburtamab for treating relapsed neuroblastoma [ID1664]	Technology appraisal guidance	TBC
One-piece closed bags for adults with a colostomy: Late Stage Assessment	Health technology evaluation	TBC
Optical Coherence Tomography to guide percutaneous coronary intervention	Interventional procedures guidance	TBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]	Technology appraisal guidance	TBC
OrganOx metra for liver transplant [ID5116]	Technology appraisal guidance	TBC
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]	Technology appraisal guidance	TBC
Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]	Technology appraisal guidance	20 August 2025
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]	Technology appraisal guidance	TBC
Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)	NICE guideline	TBC
Otilimab for treating moderate to severe rheumatoid arthritis [ID6171]	Technology appraisal guidance	TBC
Ovarian cancer QS update	Quality standard	5 February 2025
Overweight and obesity management	NICE guideline	TBC
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]	Technology appraisal guidance	TBC
Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]	Technology appraisal guidance	TBC
Palopegteriparatide for treating chronic hypoparathyroidism [ID6380]	Technology appraisal guidance	16 July 2025
Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]	Highly specialised technology	TBC
Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]	Highly specialised technology	TBC
Parsaclisib for treating relapsed or refractory marginal zone lymphoma [ID3976]	Technology appraisal guidance	TBC
Peezy Midstream for urine collection (MT446)	Medical technologies guidance	TBC
Pegcetacoplan for amyotrophic lateral sclerosis TS ID 10594	Technology appraisal guidance	TBC
Pegcetacoplan for treating geographic atrophy [ID4041]	Technology appraisal guidance	TBC
Pegylated liposomal irinotecan in combination for untreated metastatic pancreatic cancer [ID6461]	Technology appraisal guidance	TBC
Pegzilarginase for treating arginase-1 deficiency [ID4029]	Highly specialised technology	TBC
Pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID5094]	Technology appraisal guidance	20 November 2024
Pembrolizumab for adjuvant treatment of locally advanced cutaneous squamous cell carcinoma after surgery and radiotherapy ID 6473	Technology appraisal guidance	TBC
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]	Technology appraisal guidance	11 December 2024
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]	Technology appraisal guidance	TBC
Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]	Technology appraisal guidance	TBC
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]	Technology appraisal guidance	TBC
Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]	Technology appraisal guidance	TBC
Pembrolizumab with enzalutamide for treating metastatic hormone-relapsed prostate cancer [ID5103]	Technology appraisal guidance	TBC
Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]	Technology appraisal guidance	TBC
Pembrolizumab with lenvatinib for previously treated metastatic colorectal cancer [ID5112]	Technology appraisal guidance	TBC
Pembrolizumab with lenvatinib for treating EGFR, ALK or ROS1-negative metastatic non-small-cell lung cancer after a PD-1 or PD-L1 inhibitor and platinum-based chemotherapy [ID5109]	Technology appraisal guidance	TBC
Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]	Technology appraisal guidance	TBC
Pembrolizumab with lenvatinib for untreated PD-L1 positive recurrent or metastatic squamous cell head and neck cancer [ID5118]	Technology appraisal guidance	TBC
Pembrolizumab with olaparib for maintenance treatment of advanced squamous non-small-cell lung cancer [ID4006]	Technology appraisal guidance	TBC
Pembrolizumab with olaparib for maintenance treatment of non-squamous metastatic non-small-cell lung cancer after pembrolizumab with platinum-based chemotherapy [ID4028]	Technology appraisal guidance	TBC
Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after abiraterone or enzalutamide and chemotherapy [ID3814]	Technology appraisal guidance	TBC
Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873]	Technology appraisal guidance	TBC
Pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma [ID4044]	Technology appraisal guidance	28 May 2025
Pembrolizumab with platinum chemotherapy, pemetrexed and lenvatinib for untreated advanced non-squamous non-small-cell lung cancer [ID3985]	Technology appraisal guidance	TBC

Results per page

10
25
50
All